Jeremy Rubinstein

Assistant Professor

Cincinnati Children's Hospital Medical Center

United States

Research Interests

Explore related searches

Professors in United States Professors in Immunology Immunology professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Dr. Jeremy Rubinstein is an Assistant Professor at Cincinnati Children's Hospital Medical Center. His research primarily focuses on pediatric oncology with a particular interest in immunotherapy, viral infections post-transplant, and outcomes related to novel treatments for hematologic malignancies. Dr. Rubinstein's recent publications address the efficacy of virus-specific T cells, CAR-T therapies, and treatment strategies for non-Hodgkin lymphoma in children. He is dedicated to advancing clinical approaches for improving patient care in pediatric cancer treatments.

Articles (12)

Year:

2025

Year:

2025

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

UNITED STATES

View details

Patrick Hanley

Associate Professor

George Washington University

UNITED STATES

View details

Michael S. Grimley

University of Cincinnati College of Medicine

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Jeremy Rubinstein

Research Interests

Explore related searches

Contact this professor

About

Articles (12)

Outcomes with Third Party Virus Specific T-cells After the Use of Single Antigen Cell Lines to Predict HLA Restriction

Posttransplant EBV‐Positive Smooth Muscle Tumors in Children, Adolescents, and Young Adults: A Multi‐Institution Experience

The Choice of Either Conventional Chemotherapy or Inotuzumab Ozogamicin as Bridging Regimen Does Not Appear To Impact Clinical Response to CD19-Directed CAR-T Therapy in Pediatric B-ALL

Use of gemcitabine, oxaliplatin, and anti‐CD20 therapy in children and adolescents with non‐Hodgkin lymphoma unfit for intensive therapy

Durable remissions achieved with reinfusion of CD19‐directed CAR‐T despite failure to induce or maintain B‐cell aplasia and single‐center experience with reinfusion of tisagenlecleucel

Off-the-Shelf Third-Party Virus-Specific T Cell Therapy to Treat JC Polyomavirus Infection in Hematopoietic Stem Cell Transplantation Recipients

Scheduled administration of virus-specific T cells for viral prophylaxis after pediatric allogeneic stem cell transplant

Acute myeloid leukemia in SRP54‐mutated congenital neutropenia

Treatment of posttransplant lymphoproliferative disorder with poor prognostic features in children and young adults: Short‐course EPOCH regimens are safe and effective

Virus-specific T cells for adenovirus infection after stem cell transplantation are highly effective and class II HLA restricted.

Tolerance of dinutuximab therapy for treatment of high‐risk neuroblastoma in two patients with end‐stage renal disease on dialysis

Complement inhibition does not impair the clinical antiviral capabilities of virus-specific T-cell therapy

Collaborators (9)

Christopher Dandoy

Thomas Galletta

Lauren Pommert

Robin Norris

Lynn Lee

Maureen O'Brien

Catherine M. Bollard

Patrick Hanley

Michael S. Grimley

Make your next move.